SCHEMBL1009035

SCHEMBL1009035

Cc1cccc(C)c1COc1cccc(C(C)(C)C#N)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 5/20 0.44
SOD1 P00441 1/20 0.40
NR4A1 P22736 1/20 0.36
NR4A2 P43354 1/20 0.36
NR4A3 Q92570 1/20 0.36
PKM P14618 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAOB P27338 2/20 0.35
JAK2 O60674 1/20 0.35
ROCK2 O75116 1/20 0.35
PRKCQ Q04759 1/20 0.35
PRKCD Q05655 1/20 0.35
ROCK1 Q13464 1/20 0.35
BRAF P15056 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036373 0.81 MAOB (0.54) NR4A1NR4A2NR4A3PKMMAOB
SCHEMBL2008254 0.80 TP53 (0.47) SOD1ALDH1A1JAK2ROCK2PRKCQ
SCHEMBL9692881 0.78 KMT2A (0.49) ALDH1A1JAK2ROCK2PRKCQPRKCD
SCHEMBL1007786 0.77 SLC22A12 (0.43) SLC22A12SOD1NR4A1NR4A2NR4A3
SCHEMBL13282765 0.77 TSHR (0.45) CYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL955762 0.76 PKM (0.48) SLC22A12SOD1NR4A1NR4A2NR4A3
SCHEMBL1234573 0.76 NR1H4 (0.50) SLC22A12MAOB
SCHEMBL1007659 0.75 ACHE (0.44) ALDH1A1JAK2ROCK2PRKCQPRKCD
SCHEMBL1235319 0.74 SLC22A12 (0.52) SLC22A12MAOB
SCHEMBL1634516 0.73 PKM (0.46) SLC22A12SOD1NR4A1NR4A2NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 SLC22A12 139/4885SOD1 4064/4885NR4A1 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.